Standard

Mycobacterium africanum (Lineage 6) shows slower sputum smear conversion on tuberculosis treatment than Mycobacterium tuberculosis (Lineage 4) in Bamako, Mali. / Diarra, Bassirou; Kone, Mahamadou; Togo, Antieme Combo Georges; Sarro, Yeya Dit Sadio; Cisse, Aissata Boubakar; Somboro, Amadou; Degoga, Boureima; Tolofoudie, Mohamed; Kone, Bourahima; Sanogo, Moumine; Baya, Bocar; Kodio, Ousmane; Maiga, Mamoudou; Belson, Michael; Orsega, Susan; Krit, Meryam; Dao, Sounkalo; Maiga, Ibrahim Izétiegouma; Murphy, Robert L; Rigouts, Leen; Doumbia, Seydou; Diallo, Souleymane; de Jong, Bouke Catherine.

In: PLoS ONE, Vol. 13, Nr. 12, 2018, blz. e0208603.

Onderzoeksoutput: Bijdrage aan tijdschriftA1: Web of Science-artikel

Harvard

Diarra, B, Kone, M, Togo, ACG, Sarro, YDS, Cisse, AB, Somboro, A, Degoga, B, Tolofoudie, M, Kone, B, Sanogo, M, Baya, B, Kodio, O, Maiga, M, Belson, M, Orsega, S, Krit, M, Dao, S, Maiga, II, Murphy, RL, Rigouts, L, Doumbia, S, Diallo, S & de Jong, BC 2018, 'Mycobacterium africanum (Lineage 6) shows slower sputum smear conversion on tuberculosis treatment than Mycobacterium tuberculosis (Lineage 4) in Bamako, Mali', PLoS ONE, vol. 13, nr. 12, blz. e0208603. https://doi.org/10.1371/journal.pone.0208603

APA

Vancouver

Author

Diarra, Bassirou ; Kone, Mahamadou ; Togo, Antieme Combo Georges ; Sarro, Yeya Dit Sadio ; Cisse, Aissata Boubakar ; Somboro, Amadou ; Degoga, Boureima ; Tolofoudie, Mohamed ; Kone, Bourahima ; Sanogo, Moumine ; Baya, Bocar ; Kodio, Ousmane ; Maiga, Mamoudou ; Belson, Michael ; Orsega, Susan ; Krit, Meryam ; Dao, Sounkalo ; Maiga, Ibrahim Izétiegouma ; Murphy, Robert L ; Rigouts, Leen ; Doumbia, Seydou ; Diallo, Souleymane ; de Jong, Bouke Catherine. / Mycobacterium africanum (Lineage 6) shows slower sputum smear conversion on tuberculosis treatment than Mycobacterium tuberculosis (Lineage 4) in Bamako, Mali. In: PLoS ONE. 2018 ; Vol. 13, Nr. 12. blz. e0208603.

BibTeX

@article{de3ed574c7564796a250adad3a0f195e,
title = "Mycobacterium africanum (Lineage 6) shows slower sputum smear conversion on tuberculosis treatment than Mycobacterium tuberculosis (Lineage 4) in Bamako, Mali",
abstract = "OBJECTIVE: Ancestral M. tuberculosis complex lineages such as M. africanum are underrepresented among retreatment patients and those with drug resistance. To test the hypothesis that they respond faster to TB treatment, we determined the rate of smear conversion of new pulmonary tuberculosis patients in Bamako, Mali by the main MTBc lineages.METHODS: Between 2015 and 2017, we conducted a prospective cohort study of new smear positive pulmonary tuberculosis patients in Bamako. Confirmed MTBc isolates underwent genotyping by spoligotyping for lineage classification. Patients were followed at 1 month (M), 2M and 5M to measure smear conversion in auramine (AR) and Fluorescein DiAcetate (FDA) vital stain microscopy.RESULT: All the first six human MTBc lineages were represented in the population, plus M. bovis in 0.8{\%} of the patients. The most widely represented lineage was the modern Euro-American lineage (L) 4, 57{\%}, predominantly the T family, followed by L6 (M. africanum type 2) in 22.9{\%}. Ancestral lineages 1, 5, 6 and M. bovis combined amounted to 28.8{\%}. Excluding 25 patients with rifampicin resistance, smear conversion, both by AR and FDA, occurred later in L6 compared to L4 (HR 0.80 (95{\%} CI 0.66-0.97) for AR, and HR 0.81 (95{\%}CI 0.68-0.97) for FDA). In addition we found that HIV negative status, higher BMI at day 0, and patients with smear grade at baseline ≤ 1+ were associated with earlier smear conversion.CONCLUSION: The six major human lineages of the MTBc all circulate in Bamako. Counter to our hypothesis, we found that patients diseased with modern M. tuberculosis complex L4 respond faster to TB treatment than those with M. africanum L6.",
author = "Bassirou Diarra and Mahamadou Kone and Togo, {Antieme Combo Georges} and Sarro, {Yeya Dit Sadio} and Cisse, {Aissata Boubakar} and Amadou Somboro and Boureima Degoga and Mohamed Tolofoudie and Bourahima Kone and Moumine Sanogo and Bocar Baya and Ousmane Kodio and Mamoudou Maiga and Michael Belson and Susan Orsega and Meryam Krit and Sounkalo Dao and Maiga, {Ibrahim Iz{\'e}tiegouma} and Murphy, {Robert L} and Leen Rigouts and Seydou Doumbia and Souleymane Diallo and {de Jong}, {Bouke Catherine}",
note = "CPDF",
year = "2018",
doi = "10.1371/journal.pone.0208603",
language = "English",
volume = "13",
pages = "e0208603",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

RIS

TY - JOUR

T1 - Mycobacterium africanum (Lineage 6) shows slower sputum smear conversion on tuberculosis treatment than Mycobacterium tuberculosis (Lineage 4) in Bamako, Mali

AU - Diarra, Bassirou

AU - Kone, Mahamadou

AU - Togo, Antieme Combo Georges

AU - Sarro, Yeya Dit Sadio

AU - Cisse, Aissata Boubakar

AU - Somboro, Amadou

AU - Degoga, Boureima

AU - Tolofoudie, Mohamed

AU - Kone, Bourahima

AU - Sanogo, Moumine

AU - Baya, Bocar

AU - Kodio, Ousmane

AU - Maiga, Mamoudou

AU - Belson, Michael

AU - Orsega, Susan

AU - Krit, Meryam

AU - Dao, Sounkalo

AU - Maiga, Ibrahim Izétiegouma

AU - Murphy, Robert L

AU - Rigouts, Leen

AU - Doumbia, Seydou

AU - Diallo, Souleymane

AU - de Jong, Bouke Catherine

N1 - CPDF

PY - 2018

Y1 - 2018

N2 - OBJECTIVE: Ancestral M. tuberculosis complex lineages such as M. africanum are underrepresented among retreatment patients and those with drug resistance. To test the hypothesis that they respond faster to TB treatment, we determined the rate of smear conversion of new pulmonary tuberculosis patients in Bamako, Mali by the main MTBc lineages.METHODS: Between 2015 and 2017, we conducted a prospective cohort study of new smear positive pulmonary tuberculosis patients in Bamako. Confirmed MTBc isolates underwent genotyping by spoligotyping for lineage classification. Patients were followed at 1 month (M), 2M and 5M to measure smear conversion in auramine (AR) and Fluorescein DiAcetate (FDA) vital stain microscopy.RESULT: All the first six human MTBc lineages were represented in the population, plus M. bovis in 0.8% of the patients. The most widely represented lineage was the modern Euro-American lineage (L) 4, 57%, predominantly the T family, followed by L6 (M. africanum type 2) in 22.9%. Ancestral lineages 1, 5, 6 and M. bovis combined amounted to 28.8%. Excluding 25 patients with rifampicin resistance, smear conversion, both by AR and FDA, occurred later in L6 compared to L4 (HR 0.80 (95% CI 0.66-0.97) for AR, and HR 0.81 (95%CI 0.68-0.97) for FDA). In addition we found that HIV negative status, higher BMI at day 0, and patients with smear grade at baseline ≤ 1+ were associated with earlier smear conversion.CONCLUSION: The six major human lineages of the MTBc all circulate in Bamako. Counter to our hypothesis, we found that patients diseased with modern M. tuberculosis complex L4 respond faster to TB treatment than those with M. africanum L6.

AB - OBJECTIVE: Ancestral M. tuberculosis complex lineages such as M. africanum are underrepresented among retreatment patients and those with drug resistance. To test the hypothesis that they respond faster to TB treatment, we determined the rate of smear conversion of new pulmonary tuberculosis patients in Bamako, Mali by the main MTBc lineages.METHODS: Between 2015 and 2017, we conducted a prospective cohort study of new smear positive pulmonary tuberculosis patients in Bamako. Confirmed MTBc isolates underwent genotyping by spoligotyping for lineage classification. Patients were followed at 1 month (M), 2M and 5M to measure smear conversion in auramine (AR) and Fluorescein DiAcetate (FDA) vital stain microscopy.RESULT: All the first six human MTBc lineages were represented in the population, plus M. bovis in 0.8% of the patients. The most widely represented lineage was the modern Euro-American lineage (L) 4, 57%, predominantly the T family, followed by L6 (M. africanum type 2) in 22.9%. Ancestral lineages 1, 5, 6 and M. bovis combined amounted to 28.8%. Excluding 25 patients with rifampicin resistance, smear conversion, both by AR and FDA, occurred later in L6 compared to L4 (HR 0.80 (95% CI 0.66-0.97) for AR, and HR 0.81 (95%CI 0.68-0.97) for FDA). In addition we found that HIV negative status, higher BMI at day 0, and patients with smear grade at baseline ≤ 1+ were associated with earlier smear conversion.CONCLUSION: The six major human lineages of the MTBc all circulate in Bamako. Counter to our hypothesis, we found that patients diseased with modern M. tuberculosis complex L4 respond faster to TB treatment than those with M. africanum L6.

U2 - 10.1371/journal.pone.0208603

DO - 10.1371/journal.pone.0208603

M3 - A1: Web of Science-article

C2 - 30540823

VL - 13

SP - e0208603

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 12

ER -

ID: 2787978